Atara Biotherapeutics, Inc. (ATRA)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | - | 40,190 | ||
| Research and development expenses | 7,310 | 43,924 | ||
| General and administrative expenses | 6,514 | 10,421 | ||
| Cost of commercialization revenue | 554 | 7,602 | ||
| Total costs and operating expenses | 14,378 | 61,947 | ||
| Commercialization revenue | 17,575 | - | ||
| Income (loss) from operations | 3,197 | -21,757 | ||
| Other income (expense), net | 22 | 555 | ||
| Interest income | 143 | 459 | ||
| Interest expense | 972 | 1,183 | ||
| Total other income (expense), net | -807 | -169 | ||
| Income (loss) before provision for (benefit from) income taxes | 2,390 | -21,926 | ||
| Provision for (benefit from) income taxes | 3 | -17 | ||
| Net income (loss) | 2,387 | -21,909 | ||
| Unrealized gain (loss) on available-for-sale securities | - | 36 | ||
| Comprehensive income (loss) | 2,387 | -21,873 | ||
| Earnings per share, basic | 0.2 | -2.93 | ||
| Earnings per share, diluted | 0.19 | -2.93 | ||
| Weighted average shares outstanding - basic | 12,197,000 | 7,466,000 | ||
| Weighted average shares outstanding - diluted | 12,310,000 | 7,466,000 | ||